USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/9002
Title: Rolul preparatului BioR în tratamentul complex (adjuvant) al adenomului de prostată
Other Titles: Role of medication BioR in complex treatment of benign prostatic hyperplasia
Authors: Ceban, Emil
Banov, Pavel
Galescu, Andrei
Tănase, Adrian
Rudic, Valeriu
Guţu, Constantin
Issue Date: 2011
Publisher: Asociaţia chirurgilor “Nicolae Anestiadi” din Republica Moldova
Citation: CEBAN, E., BANOV, P., GALESCU, A., et.al. Rolul preparatului BioR în tratamentul complex (adjuvant) al adenomului de prostată. In: Arta Medica. 2011, nr. 2(45), pp. 14-19. ISSN 1810-1852.
Abstract: Summary. The aim of the study was to determine the efficiency of BioR medication in patients with benign prostatic hyperplasia (BPH) by monitoring serum PSA and testosterone levels, prostate volume, residual urine and International Prostate Symptom Score (IPSS) and quality of life index(QoL). The study was performed on a group of 44 male patients. Inclusion criteria in the study were: men with confirmed diagnosed BPH in outpatient treatment, patients with symptomatic obstructive and irritable symptoms and patients who agreed to this treatment with additional agreement confirmed by signature. The patients who were included in this study were divided in two groups: 24 patients in the basic group and 20 patients in the control group. Treatment administered to the main group of patients was BioR. Patients were monitored for 90 days with three visits to the doctor. Results of this dynamic study were assessed. All exposed indicators were analyzed statistically using Student test. Serum testosterone levels in study group I increased in average from 3.5 (first visit) to 4.43 (second visit) and evolved through growth figures up to the 6.85 average at the end of treatment. PSA indicators showed that statistically significant differences from the control group were constant throughout the study. In group I patients score values of IPSS and QoL decreased significantly at visit 2 and 3. With regard to prostate volume, during the evaluation we found a statistical difference only during the 3rd visit. In both indicated groups there was a decrease of residual urine dynamics, the most significant being with the incapacitated patients from the main group. Based on this study, by statistical confirmation, it can be concluded that BioR is efficient medication in patients with early stage of grade one and two benign prostatic hyperplasia. Drug action to normalize serum levels of PSA and testosterone was also found. There were established effects of improving IPSS score and QoL index.
URI: http://repository.usmf.md/handle/20.500.12710/9002
ISSN: 1810-1852
1810-1852
Appears in Collections:Arta Medica Vol. 45 No.2, 2011 ediţie specială

Files in This Item:
File Description SizeFormat 
ROLUL_preparatului_BioR_in_tratamentul_COMPLEX.pdf299.36 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback